Acute intermittent porphyria (AIP) is a neuropathic disease caused by a dominant inherited deficiency in porphobilinogen deaminase (PBGD). We investigated the expression and the degradation of the human PBGD-mutations G748A, G748C and 887insA following transfection into human SH-SY5Y neuroblastoma cells. Mutant proteins exhibited reduced protein expression compared to transfected wild-type (wt) PBGD as revealed by Western blotting. The transcription levels assessed by real-time PCR of these mutant species were identical to those of the wild type. Immunofluorescence microscopy revealed reduced cellular distribution of the mutated PBGDs in the cytosol and the nucleus in comparison to the wild-type PBGD. Enhanced cellular accumulation of the mutated and wild-type PBGDs was detected following inhibition of the proteasome by the inhibitors CLBL and hemin. Elevated expression of wt and mutated PBGD protein levels was either achieved by hemin or heme-arginate treatment. On the other hand, enhanced PBGD degradation was achieved by lead poisoning of ALAD in the SH-SY5Y cells concomitant with acceleration of proteasomal activity, most probably by ALAD participation in proteasomal regulation [G.G. Guo, M. Gu, J.D. Etlinger, 240-kDa proteasome inhibitor (CF-2) is identical to delta-aminolevulinic acid dehydratase. J Biol Chem 1994; 269:12399-402.] Our results suggest that the difference in expression between the wild-type and mutant proteins appears to be regulated on the level of protein degradation. In conclusion, we demonstrate that the PBGD cellular pool is controlled by the proteasome activity, which in turn is down regulated by hemin or up-regulated by Pb-ALAD.
Introduction
Porphyrias are a family of human inherited diseases, each associated with a partial defect in one of the heme biosynthetic enzymes. Each porphyrinopathy therefore is associated with specific metabolic abnormalities, reflected by diagnostic laboratory findings in the blood, urine and stool of the affected individual [1] . Acute intermittent porphyria (AIP) is a severe form of porphyria, and is caused by a dominant, inherited partial deficiency of the heme biosynthetic enzyme, porphobilinogen deaminase (PBGD) [2, 3] .
The frequency of AIP is around 1-10:100,000 globally, and only in a few villages in northern Sweden the frequency reaches 2:100 or 5:1000 because of a founder effect. [4, 5] . AIP is clinically associated with life-threatening neuropathy attacks, including autonomic neuropathy with abdominal pain, vomiting, constipation, hypertension, tachycardia and bladder dysfunction [6] [7] [8] . Hemin and heme-arginate are used clinically for the management of AIP, mainly to reduce the acute symptoms [5, 9] . Lead poisoning is clinically manifested by an AIP-like disorder and has been successfully treated with hemin [10] . Recently we have demonstrated that lead poisoning of neuroblastoma cells induces proteasomal degradation of PBGD which correlates with the inhibition of ALA-dehydratase [11] .
The regulation of the heme synthesis pathway is under the control of the first enzyme, ALA-synthetase, and the last enzyme, ferrochelatase [1] [2] [3] 5, 7, 8] . It has been reported that hemin is a specific inhibitor of the catalytic activity of the proteasome [12, 13] , while ALAD (ALA-dehydratase) acts as the CF-2 regulatory subunit of the proteasome [14] . In the presence of hemin, polyubiquitinated cystic fibrosis transmembrane conductance regulator (CFTR) remains undegraded by the proteasome in cell-free and microsomal CFTR systems, indicating that hemin inhibits the catalytic activity of the core proteasome enzymes [15] .
The PBGD enzyme is known to be the synthesis rate-limiting determinant of the heme molecule. Its gene encodes two isoenzymes formed by an alternative splicing process. The first is a housekeeping form that is available in all tissues, whereas the second is specific only for erythroid cells [16] . To date, according to "Gene Mutation Database", 246 mutations have been described within the PBGD gene, including deletion/ insertion and point mutations [17] [18] [19] [20] [21] ]. An experimental model based on PBGD-deficient mice (PBGD −/− ) showed that these mice develop impairment of motor coordination, and muscle weakness [22] . The prevailing theories are that the neuropathy in AIP may be due to a lack of heme in the nervous tissue, to an excess of the heme pathway intermediates, ALA and PBG, or may be induced indirectly by the metabolic consequences of heme deficiency in the liver [23, 24] .
We have shown that PBGD is imported into the nucleus of various cell lines and of primary cells, and has a nuclear function separate from the cytoplasmic pool, where PBGD participates in heme synthesis [25] . Moreover, using a twohybrid screen, we revealed an interaction between PBGD and the nuclear Ran-binding factor, RanBPM, whose function is as yet unknown [26] . Much is known about the biochemical consequences of PBGD defects; however, the origin of the neurological manifestations remains unresolved.
The aims of the present study were to examine the transcription, expression and sub-cellular localization of three common AIP mutations, G748A, G748C and 887insA, which were constitutively expressed in a human neuroblastoma cell line. We examined the inhibitory effect of hemin/ heme-arginate and Clasto-lactacystin B-lactone (CLBL) on proteasomal degradation of PBGD and the consequences of hemin-mediated inhibition on the expression of mutant PBGD forms. Alternatively, we accelerated the proteasome activity by lead poisoning of the second enzyme of the heme biosynthetic pathway, 5-aminolevulinic acid-dehydratase (ALAD). We demonstrate that the PBGD cellular pool is an example of a regulatory mechanism controlled by hemin via the proteasome.
Materials and methods

Cell culture
Human SH-SY5Y neuroblastoma cells were grown in tissue culture plates (Corning, Staffordshire, UK) in DMEM medium (Biological Industries, Kibbutz Beit-Haemek, Israel), supplemented with 10% fetal calf serum and antibiotics, and incubated at 37°C in a humidified atmosphere with 8% CO 2 . Cells were treated with 10 μM Clasto lactacystin β-lactone (Sigma), 100 μM hemin (Sigma) or 100 μM heme-arginate (Orphan Europe).
Construction of mutated-PBGD constructs
The coding region of the human PBGD was amplified from the PBGDexpression vector as described [25] , with the forward primer: 5′-CGGGAT-CCCGGCCGCCACCATGGCTTACCCATACGATGTTCCAGATTACGC-TATGTCTGGTAACGGCAATGCGGC-3′ containing the HA-tag, and reverse primer: 5′-CGGGATCCCGTTAATGGGCATCGTTAAGCTGCCG-3′. The 1138 bp PCR product was inserted into the pLY-3 vector, as described [25] , yielding a new plasmid named pHA-PBGD plasmid, which expresses the wildtype PBGD in mammalian cells. The PBGD mutants were amplified (forward: 5′-GCTTCGCTGCATCGCTCAAAGGGCCTTCCTGAG-3′ and reverse: 5′-CTCAGGAAGGCCCTTTGAGCGATGCAGCGAAGC-3′ for the G748C mutant, forward: 5′-GCTTCGCTGCATCGCTAAAAGGGCCTTCCTGAG-3′ and reverse 5′-CTCAGGAAGGCCCTTTTAGCGATGCAGCGAAGC-3′ for the G748A mutant, forward: 5′-CAAGAGACCATGCAAGGCTACCATCCATGTCC-3′ and reverse: 5′-GGACATGGATGGTAGCCTTGCATGGTCTCTTG-3′ for the 887insA mutant) using the circle pHA-PBGD plasmid, by the high fidelity PfuTurbo® DNA polymerase (Stratagene, La Jolla, CA). Immediately after the PCR reaction, 10 units of DpnI enzyme were added to each reaction for 1 h at 37°C, for digestion of methylated DNA sequences. The DNA products were transformed into competent bacterial cells using the heat-shock method. The cells were plated on LB medium containing Kanamycin. Constructs were verified by sequencing (Weizmann Institute Biological Services, Rehovot, Israel).
Stable cell transfection
The plasmids were transfected into SH-SY5Y cells, using lipofectamine reagent (GIBCO-BRL, Gaithersburg, MD) according to the manufacturer's protocol. For stable transfection, selective medium containing 1100 μg/ml G418 (GIBCO-BRL, Gaithersburg, MD) was added to the cells 24 h posttransfection. The surviving G418-resistant colonies on each plate were then sub-cloned by dilution and grown to establish the sub-lines. For selection maintenance, the cells were selectively grown in a medium containing 200 μg/ml G418.
RT-PCR of PBGD-mutants
Total RNA was extracted from PBGD-mutant expressing SH-SY5Y cells using an RNeasy Mini Kit (Qiagen GmbH, Hilden, Germany). RT-PCR was carried out using RT-PCR beads (Amersham Pharmacia, Piscataway, NJ) according to manufacturer's instructions, using 5′-ATGGCTTACCCATAC-GATGTT-3′ forward primer and 5′-TTAATGGGCATCGTTAAGCTG-3′ reverse primer.
Real-time quantitative RT-PCR of PBGD mutants
An amount of 3 μg total RNA extracted from mutant-PBGD expressing SH-SY5Y cells was reverse transcribed with Expand reverse transcriptase (Roche), using the reverse primers for PBGD and β-actin (20 pmol of each). The forward primer for PBGD was homologous to the HA-tag: 5′-CTT ACC CAT ACG ATG TTC CAG AT-3′, and the reverse primer was: 5′-GTA CCC ACG CGA ATC ACT CT-3′. For the reference gene, β-actin, we used the forward primer 5′-TCA CCC ACA CTG TGC CCA TCT AC-3′ and reverse primer: 5′-CAG CGG AAC CGC TCA TTG CCA AT-3′. Real-time quantitative PCR was carried out with DyNAmo HS SYBR Green qPCR kit (Finnzymes, Finland). The amplifications were performed in a thermocycler (DNA Engine Opticon 2, MJ Research) with the following thermal profile: 95°C for 15 min followed by 40 cycles of 94°C for 10 s, 59°C for 25 s, 72°C for 30 s, plate read, 78°C for 1 s, melting curve program from 65°C to 95°C, with a heating rate of 0.5°C/s, cooling program down to 30°C. Each sample was replicated three to five times. Standard curves constructed with serial dilutions of cDNA were generated for each transcript in triplicates. Each assay included a non-RT control and a non-template control.
Data acquisition was performed using the Opticon Monitor 2 software. The relative expression ratio of the genes of interest was computed by use of the following equation [27] :
RT-PCR data were tested for statistical significance by a pair-wise fixed reallocation randomization test as implemented by REST [28] .
PBGD enzymatic activity assay
Cells were detached from plates and centrifuged, pellets were resuspended and homogenized in 250 μl 50 mM Tris (pH 8.2), containing 0.2% Triton X-100. In brief, PBGD was assayed by determining the absorbance of uroporphyrin formed by light-induced oxidation of uroporphyrinogen, which is the immediate product of the enzymatic deamination. PBGD specific activity was calculated as described [25] , as pmol uroporphyrin formed/mg protein/h (ex. 409 nm, em. 595 nm).
Western blotting
Proteins were quantified using the Bradford assay (Bio-Rad, Hercules, CA) and resolved on a 12% polyacrylamide gel. The proteins were then transferred onto nitrocellulose membranes using a semi-dry transfer apparatus (Bio-Rad, Hercules, CA). After blocking, the membranes were incubated with primary monoclonal antibodies against the HA-tag (Berkeley Antibody Company, Richmond, CA) or actin (Sigma) or rabbit anti-PBGD antibodies (a generous gift from HemeBiotech, Sweden) and HRP anti-mouse/rabbit secondary antibody (Jackson Immuno-Research, West Grove, PA). Immuno-reactive proteins were visualized with either SuperSignal® West Pico (Amersham Pharmacia, Piscataway, NJ) or LumiGLO® (KPL, Gaithersburg, MD), according to manufacturer's instructions. Densitometric analysis was performed with "Image J" software.
PBGD immunolabeling
SH-SY5Y cells expressing PBGD mutants were fixed using 4% paraformaldehyde, subsequently washed and incubated for 1 h with blocking solution containing 0.5% Triton X-100, 1% BSA, and 10% FCS in PBS, following incubation with anti-HA-tag antibody overnight at 4°C and thereafter with goat anti-mouse secondary antibody (Alexa Fluor® 568, Molecular Probes). The cells were visualized by fluorescence microscopy (Vanox AHBT3 microscope). As a control, cells were incubated with only the secondary antibody.
Proteasome activity assay
Cells were detached from plates and centrifuged, pellets were resuspended and homogenized in 250 μl 100 mM Tris (pH 7.5), containing 1% Triton X-100. Lysates were incubated with 13 μM of the fluorogenic proteasome substrate N-Succinyl-Leu-Leu-Val-Tyr-7-Amido-4-Methylcoumarin (Sigma) in the same buffer but without detergent for 1 h at 37°C with shaking. Ice-cold ethanol (100%) was added, and the samples were analyzed by a HPLC system LaChrom D-7000 (Merck Hitachi) utilizing a FL detector L-7480. Data acquisition was performed by the HSM software and further analyzed by Microsoft Excel.
ALAD enzymatic activity assay
Cells were washed and detached from plates using 0.1 M Tris (pH 7.2) containing 0.25 M sucrose. After centrifugation, pellets were resuspended in 2), for 2 h at 37°C with shaking. The reaction was stopped by addition of 6% TCA and formed PBG was developed by the Ehrlich's reagent [29] and measured spectrophotometrically (em. 555 nm) (Spectronic Instruments, Leeds, UK). ALAD specific activity was calculated as pmol PBG formed/mg protein/ 2 h units [30] .
Results
Expression of mutated-PBGD constructs in neuroblastoma cells
We constructed three PBGD-expression vectors tagged to hemagglutinin, encoding the PBGD mutants G748A, G748C and 887insA, which are responsible for severe phenotypes of human AIP [31] [32] [33] . The mutant vectors, as well as the wildtype PBGD, were constitutively over-expressed within human neuroblastoma SH-SY5Y cells; we chose this cell line to reflect the neuropathology of AIP. Protein expression was analyzed by Western blotting, using anti-HA antibodies. The results show high levels of wild-type PBGD protein (44 kDa), while the mutant proteins G748A and G748C (glutamine mutated to lysine or alanine) displayed a weak band of 44 kDa proteins detected by HA-tag antibodies ( Fig. 1A and B) . The truncated PBGD mutant, 887insA (frame-shift mutation), was found to express a very weak 35 kDa band.
mRNA expression of wt and mutated HA-PBGDs
The reduced protein expression of the mutated PBGD forms could be attributed to reduced mRNA expression or to the enhanced degradation of the proteins. RT-PCR assay, using a forward primer containing the HA sequence at the 5′ end, and a reverse primer that is homologous to the end of the PBGD sequence, showed that the cells expressing the mutant and the wild-type contain identical levels of PBGD transcripts ( Fig. 2A) . In order to validate that mRNA levels of the mutants compared to the wild-type are not changed at the transcriptional level, we carried out real-time PCR. The realtime PCR assay using a forward primer containing the HA sequence at the 5′ end, and a reverse primer that is homologous to a sequence within the gene, showed negligible upregulation of two of the three mutants analyzed, as calculated by REST [28] (Fig. 2B) . The virtually identical mRNA levels of these PBGD vectors indicate that the reduced protein quantities of the mutants are not due to reduced transcription.
PBGD enzymatic activity of the cells expressing PBGD mutants
PBGD activity in SH-SY5Y cells expressing the mutants was moderately reduced in the G748C, G748A and 887insA mutants, respectively, compared to the non-transfected cells (Fig. 3) . In the wild-type PBGD over-expressing cells, the enzymatic activity increased only moderately compared to the non-transfected cells. The reduction in the enzymatic activity points to a dominant negative effect of the mutants.
Mutant PBGDs are distributed in the nuclear and cytosolic compartments
PBGD acts as the third enzyme of the heme synthesis pathway [34] . We have previously demonstrated the localization of wt-PBGD in the cytosol and the nucleus of different cells [25, 26] . Fluorescence microscopy (Fig. 4 ) demonstrated similar distribution of the three mutants ( Fig. 4C-E) and of the wildtype PBGD (Fig. 4B) in the cell compartments. Image acquisition was performed under optimal and identical illumination conditions to prevent over-excitation and emission-saturation of fluorescence, while giving a semi-quantitative comparison of the different images. The fluorescence intensity of the images of Fig. 4 clearly depicts reduced abundance of the mutant PBGD forms as compared to the wt-PBGD in the cytosol and nucleus.
The effect of proteasomal activity inhibition on HA-PBGD expression
The low levels of mutant protein expression in addition to constant mutant mRNA transcription, led us to suspect that a degradation mechanism might be involved in the reduced levels of mutant proteins. Thus, in order to determine whether mutant-PBGDs levels increase under proteasome inhibition we used two known proteasome inhibitors, CLBL and the therapeutic agents hemin and heme-arginate applied in AIP therapy [5, 9] . Fig. 5A demonstrates the hemin-induced inhibition of the proteolytic activity in SH-SY5Y cells, and the increase in wild-type-PBGD protein levels in a timedependent manner of hemin-treatment is shown in Fig. 5B and C, as detected by anti-HA-tag antibody. Furthermore, CLBL-treatment of cells expressing the wild-type-PBGD resulted in an accumulation of HA-PBGD (Fig. 6A and B) , similarly to the effect of hemin in the same experiment. The protein levels of the mutated PBGDs, G748A/C and 887insA, were markedly increased by either CLBL, hemin or hemearginate treatment (Fig. 6C-H) , indicating a noticeable accumulation of the mutated PBGDs in the cells as a result of proteasome inhibition by either of the three proteasomal inhibitors. 3.6. The acceleration of proteasome activity by lead poisoning and its effect on endogenous wt-PBGD Lead poisoning is a well-known cause of AIP-like symptoms in human due to inhibition of ALAD [34] , which is reverted by the cofactor Zn 2+ [35] . Recently, we have demonstrated that SH-SY5Y cells exposed to lead acetate for 72 h reveal an inhibition of ALAD enzymatic activity to less than 40% [11] , and an acceleration of proteasomal activity to more than 200%. Fig. 7A presents the correlations between ALAD, PBGD and proteasomal activities under lead poisoning conditions. The sharp reduction in ALAD activity was observed at the low concentration of 1 μM lead acetate and was accompanied by a marked acceleration of proteasomal activity. The slope of the concomitant reduction in PBGD activity is moderate, reaching the maximum at a concentration of 10 μM lead acetate. The reduction of PBGD activity is due to the degradation of PBGD (Fig. 7B) . This result implies that the reduced expression of PBGD under Pb 2+ -poisoning is due to increased PBGD degradation which is a similar effect seen in the clinical condition of AIP post lead poisoning.
Discussion
To date, PBGD-deficiency and its relation to the pathogenesis of neurological dysfunction in AIP syndromes remain elusive. Two prevailing hypotheses have to be considered, the one that accumulation of ALA (a precursor of heme synthesis) is toxic to neuronal tissue, and the other that a decrease in heme and hemeproteins in the nervous system causes the pathology [36] [37] [38] . The second hypothesis, proposing heme deficiency as the fundamental origin for altered physiological activities, has to be assessed.
The present results revealed two main pieces of evidence, the one, low protein levels of mutant PBGD proteins compared to the wild-type as analyzed by Western blotting and immunolabeling; and the second, constant mRNA levels of the mutant PBGDs (Figs. 1, 2, and 4) . In general, when low protein levels are measured, while constant mRNAs are assessed, one may assume that low translation rate or high degradation of the protein is the basis of this phenomenon. Furthermore, it is conceivable that low levels of mutated PBGD proteins are due to increased proteasomal degradation of the abnormal proteins.
The over-expression of proteins may vary according to the transfection technique which may produce a transient transfection with the vector or after selection will end up with a stably transfected cell line. It is well documented that variable to high (15-200%) PBGD enzymatic activity is achieved after transient transfection with the wt-PBGD vector [39, 40] . In general, stably transfected cells produce lower amounts of the transfected protein which may also vary with the number of the integrated plasmid copies, as can be seen in the present results.
The recognition that abnormal proteins are degraded by the proteasome machinery is well documented and is dependent on ubiquitination of the target protein [41] . We examined the possibility that abnormal PBGD forms are degraded via the proteasome machinery. Constitutive PBGD mutant expressing SH-SY5Y cells were therefore treated with the cell permeable, highly specific 20S proteasome inhibitor CLBL [42, 43] , or with the therapeutic agents hemin and heme-arginate used in clinical therapy of AIP and lead poisoning [5, 9, 10] . Following treatment with either hemin, heme-arginate or CLBL, the over-expressed PBGD mutants accumulated dramatically, as detected by Western blotting (Fig. 6C-H) . The wild-type PBGD also accumulated after hemin or CLBL treatment (Fig. 6A and  B) . This finding can explain the low levels of mutant expression compared to the high levels of the wild-type PBGD detected by Western blotting using the HA-tag antibodies (Fig. 1A and B) . We have recently shown the opposite phenomenon following lead intoxication; ALA-dehydratase activity was inhibited and consequently high proteasomal activity was revealed [11] . We show here that lead acetate induced a reciprocal effect, the inhibition of ALAD activity accelerating the proteasomal activity which led to increased PBGD degradation. The possible underlying mechanism for this phenomenon is the finding that the ALA-dehydratase enzyme is identical to the proteasomal inhibitory protein complex CF-2 as reported by Guo et al. [14] . In a recent review ALAD is listed among protein regulators of the proteasome which control the intensity of its activity in the cell [44] . Lead poisoning and acute intermittent porphyria (AIP) exhibit similar neurologic manifestations; despite their similarities, the possible pathophysiologic connection between AIP and lead poisoning is not known [45] . Intravenous hematin administration produces biochemical improvement in AIP, and similarly in lead intoxication hematin administration results in significant diminution of urinary ALA and coproporphyrin excretion [10] .
In conclusion, this study provides evidence that mutant PBGDs are degraded through the proteasomal pathway which in turn can be blocked by hemin and thus up-regulate PBGD abundance in the cells, whereas Pb 2+ poisoning enhances proteasomal activity and PBGD degradation. We suggest that successful clinical use of hemin/heme-arginate is related to the reduced proteasomal degradation of AIP mutant proteins which triggers cellular increase of PBGD.
